AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00000727
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000727
Drug: Pyrimethamine
RxNorm normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000727
Drug: Sulfamethoxazole/Trimethoprim
RxNorm normalized name: SULFAMETHOXAZOLE/TRIMETHOPRIM
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000727
Drug: Sulfadoxine/Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000727
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05189730
Drug: Tirelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of Tirelizumab (200mg administered as an intravenous infusion over 30 minutes per 3 weeks), D1.
Trial: NCT05189730
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two cycles of paclitaxel (135mg/m2 administered as an intravenous infusion per 3 weeks), D1.
Trial: NCT05189730
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two cycles of carboplatin(AUC=5 administered as an intravenous infusion per 3 weeks) D1.
Trial: NCT04968184
Drug: KBP-5074
RxNorm normalized name: KBP-COVID-19
DrugBank: KBP-COVID-19 (DB15858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD.
Trial: NCT05209529
Drug: olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: olaparib 300 mg per os BID
Trial: NCT05209529
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: durvalumab 1500 mg IV Q4 weeks
Trial: NCT06765694
Drug: Botulinum toxin injection
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type B (DB00042)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: first injection was done under ultrasound control in the extensor carpi radialis brevis (ECRB). The second one if necessary was subordinated to clinical examination and focused in one or more of the following: ECRB, extensor digitorum communis, supinator.
Trial: NCT06361329
Drug: Homoharringtonine
RxNorm normalized name: Homoharringtonine
DrugBank: Omacetaxine mepesuccinate (DB04865)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT06361329
Drug: venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally by mouth
Trial: NCT06361329
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: subcutaneous injection or Intravenous infusion
Trial: NCT06361329
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous injection
Trial: NCT06361329
Drug: Vindesine
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT06361329
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT06361329
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion or orally
Trial: NCT06361329
Drug: L-ASP
RxNorm normalized name: L-Asp
DrugBank: Aspartic acid (DB00128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT05934292
Drug: Enlicitide Decanoate
RxNorm normalized name: decanoic acid
DrugBank: Capric acid (DB03600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose
Trial: NCT05522894
Drug: AK104
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg/kg IV every 3 weeks (Q3W)
Trial: NCT05522894
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m2 IV every 3 weeks (Q3W)
Trial: NCT05522894
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175mg/m2 IV every 3 weeks (Q3W)
Trial: NCT06786312
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg, P.O, qd, 21 days per cycle;
Trial: NCT06786312
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg or 1200mg ivgtt, d1, 21 days per cycle;
Trial: NCT06786312
Drug: Etoposide Injection
RxNorm normalized name: etoposide Injection
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mg/m\^2 ivgtt for the first, second and third consecutive days, 21 days per cycle.
Trial: NCT06786312
Drug: Carboplatin Injection
RxNorm normalized name: Carboplatin Injection
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1 administration, AUC=5, intravenous infusion; One treatment cycle every 21 days.
Trial: NCT06767813
Drug: TQB2868 injection+Gemcitabine injection+ Albumin paclitaxel injection+ Anlotinib capsules
RxNorm normalized name: paclitaxel Injection
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TQB2868 injection is an anti-PD 1/growth factor (GF)-β Receptor Type II (TGF-βRII) bifunctional fusion protein.
Trial: NCT06782594
Drug: Mosapride Citrate Injection(high)
RxNorm normalized name: mosapride
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride Citrate Injection, iv, 8mg, bid, for 3 to 5 days
Trial: NCT06782594
Drug: Mosapride Citrate Injection(low)
RxNorm normalized name: mosapride
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride Citrate Injection, iv, 4mg, bid, for 3 to 5 days
Trial: NCT06792422
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive oral semaglutide once daily.~1. Starting dose 3 mg/day for one month (day 1-28)~2. Intermediate dose 7 mg/day for one month (day 29-56)~3. Maintenance dose 14 mg/day (day 57-182)
Trial: NCT05870059
Drug: Propolis mouthwash
RxNorm normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After scaling and root planning at the baseline visit, patients were prescribed to use 5ml of propolis mouthwash twice a day for 6 weeks. patients were also prescribed to not eat and drink anything for half an hour after the rinse.
Trial: NCT05870059
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After scaling and root planning at the baseline visit, patients were prescribed to use chlorhexidine mouthwash twice a day for 6 weeks. patients were also prescribed to not eat and drink anything for half an hour after the rinse.
Trial: NCT03259633
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: open-label, single-arm, multicenter intermediate access protocol
Trial: NCT00000648
Drug: Penicillin G potassium
RxNorm normalized name: Penicillin G Potassium
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000648
Drug: Ceftriaxone sodium
RxNorm normalized name: Ceftriaxone Sodium
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05079620
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If there is low risk for P. aeruginosa and/or methicillin-resistant staphylococcus aureus (MRSA), as deemed by the treating team: Ceftriaxone 2 g IV, every 24 hours for 5 days
Trial: NCT05079620
Drug: Amoxicillin clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At any point after 24 hours, clinicians may (but are not required to) transition stable patients on ceftriaxone to the oral agent Amoxicillin + clavulanate (Augmentin) 875 mg PO or per feeding tube, twice daily for the remainder of 5 days
Trial: NCT05079620
Drug: Cefepime
RxNorm normalized name: Cefepime
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Cefepime 2 g IV, every 8 hours for 5 days, plus vancomycin
Trial: NCT05079620
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Vancomycin IV, dosed by trough or AUC/MIC (area under the curve/minimum inhibitory concentration) monitoring for 5 days, plus cefepime. Order nasal MRSA swab and consider discontinuing vancomycin if MRSA swab is negative.
Trial: NCT06765902
Drug: N-803
RxNorm normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A subcutaneous injection of an IL-15 superagonist.
Trial: NCT06765902
Drug: ETBX-071
RxNorm normalized name: ETBX-041
DrugBank: ETBX-041 (DB17182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A subcutaneous injection of a prostate-specific antigen (PSA) adenovirus vaccine.
Trial: NCT06765915
Drug: Avapritinib
RxNorm normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After allo-HSCT, CBF-AML patients who have kit mutation would receive avapritinib for maintenance therapy.
Trial: NCT05841420
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks or gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks
Trial: NCT05841420
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-Paclitaxel: 100mg/m2 on day 1, 8 and 15 every 4 weeks
Trial: NCT05079620
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At any point after 24 hours, clinicians may (but are not required to) transition stable patients on cefepime to levofloxacin PO or per feeding tube, 750 mg every 24 hours for the remainder of 5 days
Trial: NCT04118153
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept will be administered by subcutaneous injections weekly for 3 months. Dosing is according to body weight at screening visit and will be administered as follows: up to 25 kg receive 50 mg (0.4 mL); 25 to \<50 kg receive 87.5 mg (0.7 mL), and \> 50 kg receive 125 mg (1.0 mL) per dose.
Trial: NCT01085851
Drug: Dexchlorpheniramine 1% lotion
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small amount applied over the lesion twice a day for 7 days
Trial: NCT01085851
Drug: Dexchlorpheniramine 1% cream
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small amount applied over the lesion twice a day for 7 days
Trial: NCT05903352
Drug: Continue the antimicrobial treatment
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue the antimicrobial treatment for a duration predetermined by the investigator (usual practice, at least 5 days of treatment in total).
Trial: NCT05067478
Drug: Vibegron
RxNorm normalized name: Vibegron
DrugBank: Vibegron (DB14895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vibegron to be administered.
Trial: NCT05238116
Drug: PC945
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sterile aqueous liquid for Nebulization
Trial: NCT05545280
Drug: Neostigmine with glycopyrrolate
RxNorm normalized name: glycopyrrolate / neostigmine Injectable Solution
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion
Trial: NCT05545280
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administration by intravenous infusion
Trial: NCT06483789
Drug: HB-1
RxNorm normalized name: dextromethorphan hydrobromide 1 MG/ML
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
Trial: NCT06483789
Drug: Telmisartan Only Product in Oral Dose Form
RxNorm normalized name: Telmisartan only product in oral dose form
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan will be supplied as a single active pharmaceutical ingredient tablet.
Trial: NCT06483789
Drug: Verapamil Only Product in Oral Dose Form
RxNorm normalized name: Verapamil only product in oral dose form
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil will be supplied as a single active pharmaceutical ingredient tablet.
Trial: NCT05732506
Drug: Edoxaban
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: There are not intervention.
Trial: NCT06555328
Drug: CSU high dose treatment
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSU high dose treatment
Trial: NCT06555328
Drug: CSU non responders IgE - high dose treatment
RxNorm normalized name: marine non-gelling gelatin, high MW
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSU non responders IgE - high dose treatment
Trial: NCT06555328
Drug: HS low dose treatment
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HS low dose treatment
Trial: NCT06555328
Drug: HS medium dose treatment
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS medium dose treatment
Trial: NCT06555328
Drug: HS high dose treatment
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS high dose treatment
Trial: NCT04997525
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined with estradiol
Trial: NCT04997525
Drug: Follitropin Alfa
RxNorm normalized name: Follitropin Alfa
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined with hCG
Trial: NCT04997525
Drug: Chorionic Gonadotropin, Alpha
RxNorm normalized name: Human chorionic gonadotropin, alpha subunit
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In either natural cycle or combined with Follitropin Alfa
Trial: NCT06295952
Drug: Pasireotide
RxNorm normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days.
Trial: NCT05552651
Drug: Envafolimab
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg,sc,d1,Q3W;
Trial: NCT05552651
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 130mg/m2,iv,D1,D8,Q3W
Trial: NCT05552651
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC=5, iv,D1,Q3W
Trial: NCT04994132
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04994132
Drug: Vinorelbine Tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05706506
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06747390
Drug: Lidocaine 1% Injectable Solution
RxNorm normalized name: lidocaine 1% injectable solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1% lidocaine will be injected under direct visualization (not exceeding the maximum tolerated dose of 4.5 mg/kg body weight) into the primary tumor with the aim to distribute the lidocaine evenly into the tumor.
Trial: NCT06746870
Drug: Chemotherapy (pemetrexed + cisplatin/carboplatin)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-squamous non-small cell lung cancer (NQ-NSCLC): Pemetrexed 500 mg/m2 in combination with carboplatin (AUC 5-6) or cisplatin (75 mg/m2), intravenous infusion, Q3W, for 4 cycles, followed by maintenance treatment with pemetrexed
Trial: NCT06746870
Drug: Chemotherapy (paclitaxel + cisplatin/carboplatin)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Squamous non-small cell lung cancer (SQ-NSCLC): Paclitaxel 175 mg/m2 + carboplatin (AUC 5-6) or cisplatin (75 mg/m2), intravenous infusion, Q3W, for 4 cycles.
Trial: NCT06746870
Drug: Chemotherapy(Nab-paclitaxel)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel, 100 mg/m2, 4 weeks as a cycle, administered on D1, 8, and 15 of each cycle.
Trial: NCT04712097
Drug: Mosunetuzumab
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12
Trial: NCT04712097
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)
Trial: NCT04712097
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive IV rituximab on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11
Trial: NCT04712097
Drug: Tociluzumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events
Trial: NCT05566041
Drug: RRx-001 + eLOOP Device
RxNorm normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device~Drug: Cisplatin/carboplatin plus etoposide Standard of care platinum doublet chemotherapy
Trial: NCT05566041
Drug: Cisplatin/carboplatin plus etoposide
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care platinum doublet chemotherapy
Trial: NCT06019728
Drug: AGALSIDASE BETA (GZ419828)
RxNorm normalized name: Agalsidase Beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Lyophilized powder for reconstitution Route of administration: IV infusion
Trial: NCT06019728
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet or solution; Oral
Trial: NCT06019728
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet or solution; Oral
Trial: NCT06019728
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet or chewable tablet or oral granules; Oral
Trial: NCT06019728
Drug: Loratadine
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet or chewable tablet; Oral
Trial: NCT06019728
Drug: Cetirizine
RxNorm normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet or oral solution; Oral
Trial: NCT06019728
Drug: Fexofenadine
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet or oral suspension; Oral
Trial: NCT05477589
Drug: clofarabine, fludarabine and busulfan, CloFluBu
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: combination of clofarabine, fludarabine and busulfan in which two alkylators are replaced by antimetabolites (CloFluBu, experimental arm)
Trial: NCT06100822
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg capsules of Metformin Extended Release
Trial: NCT06266767
Drug: Levobupivacaine and Fentanyl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Programmed Intermittent Epidural Bolus
Trial: NCT05116774
Drug: Eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intravenous infusion per current dose regimen
Trial: NCT05116774
Drug: Ravulizumab
RxNorm normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intravenous infusion per current dose regimen